News & Events

Press Releases

November 30, 2021

Isarna Therapeutics Announces First Patient Enrolled in International Phase 2a Clinical Study in Ophthalmology Indications Wet AMD and DME

Isarna Therapeutics today announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase 2a clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

September 30, 2021

Isarna Therapeutics Appoints Claus Schalper as CEO

Isarna Therapeutics today announced the appointment of Claus Schalper as Chief Executive Officer. Mr. Schalper joins Isarna with over 20 years of experience as an executive and serial entrepreneur in the life science and biotech industries. His appointment expands Isarna’s management team, which includes Prof. Marion R. Munk as Chief Medical Officer, Dr. René Rückert as Chief Operating Officer and Chris Huiskamp as Chief Financial Officer.

Publications

Our scientific publications concerning transforming growth factor-beta (TGF-β):

June, 2021

Looking beyond the standard of care for eye diseases

Isarna Therapeutics’ antisense therapy targeting transforming growth factor beta 2, ISTH0036, is about to enter phase 2 clinical development for two retinal diseases: wet age-related macular degeneration and diabetic macular edema.

www.nature.com/biopharmdeal | June 2021 | B11

May, 2021

Long term safety and efficacy of ISTH0036 a selective TGF β2 blocking antisense oligonucleotide in
preclinical and Phase 1 clinical studies.

Rene Rückert, MD, MBA, Marion R. Munk, MD, PhD, FEBO, Katja Wosikowski, PhD, and Michel Janicot, PhD

ARVO 2021 Meeting, May 1-7, Virtual Meeting

2017

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.

Pfeiffer N, Voykov B, Renieri G, Bell K, Richter P, Weigel M, Thieme H, Wilhelm B, Lorenz K, Feindor M, Wosikowski K, Janicot M, Päckert D, Römmich R, Mala C, Fettes P, Leo E.

PLoS One. 2017 Nov 30;12(11):e0188899. doi: 10.1371/journal.pone.0188899. eCollection 2017.

2017

Extended preclinical ocular biodistribution and pharmacodynamic profile of ISTH0036, an antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2) for the treatment of ophthalmic diseases

WOSIKOWSKI, K., KORBMACHER, B., KRAMPERT, M., ROEHL, I., AND JANICOT, M.

Presented at ARO 2017, Nr 5702

2017

Combining ISTH0036, an antisense oligonucleotide targeting Transforming Growth Factor beta 2 (TGF-β2) mRNA, with aflibercept as novel treatment strategy for neovascular retinal diseases

Michel Janicot, Giedrius Kalesnykas, Eugen Leo, Petra Fettes, Simon Kaja, and Katja Wosikowski

Presented at ARVO 2017 Nr. 236

2016

A Phase I First-in-Human single ascending dose study of ISTH0036, a potent and selective antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2) for the treatment of primary open-angle glaucoma

Voykov, B., Lorenz, K., Schuart, C., Richter, P., Wilhelm, B., Choritz, L., Prokosch-Willing, V., Fettes, P., Leo, E. and Pfeiffer, N.

ARVO Annual Meeting, Seattle, WA, USA. May 1 – 5 2016

2016

Anti-Metastatic Activity of ISTH0047 – a Potent and Selective TGF-β2 Antisense Oligonucleotide – in Syngeneic Lung Metastatic Model of Mouse 4T1 Mammary Carcinoma

Wosikowski K., Hasenbach, K., Petschenka, J., Barea Roldán, D., Kreiter, S., Sahin, U., Serin, G., Redon, J.O., Hillairet de Boisferon, M., Bichat, F., Korhonen, H., Janicot, M.

AACR Annual Meeting, New Orleans, LA. USA. April 16-20 2016

2016

TGF-β1 and TGF-β2 abundance in liver diseases of mice and men

Dropmann A., Dediulia T., Breitkopf-Heinlein K., Korhonen H., Janicot M., Weber SN., Thomas M., Piiper A., Bertran E., Fabregat I., Abshagen K., Hess J., Angel P., Coulouarn C., Dooley S., Meindl-Beinker NM.

Oncotarget, January 2016, DOI: 10.18632/oncotarget.6967

2015

TGF-β isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity.

Pfeiffer N, Voykov B, Renieri G, Bell K, Richter P, Weigel M, Thieme H, Wilhelm B, Lorenz K, Feindor M, Wosikowski K, Janicot M, Päckert D, Römmich R, Mala C, Fettes P, Leo E.

Oncotarget, September 2015, DOI: 10.18632/oncotarget.5780

2015

Preclinical Profile of ISTH0036, a Potent and Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-β2) for the Treatment of Ophthalmic Diseases

Wosikowski, K., Hasenbach, K., Allais, L., Fant, P., Bellebeau, F., Truchot, N., Voute, H., Krampert, M., Roehl, I., Vornlocher, HP., Jaschinski, F., Korhonen, H., Vercruysse, K., Fettes, P., Mala, C., Leo, E. and Janicot, M.

ARVO, Denver, USA, May 7 2015

2015

Targeting Transforming Growth Factor beta 2 (TGF-β2) Isoform with ISTH0036 – a Potent and Selective Antisense Oligonucleotide – for the Treatment of Glaucoma

Hasenbach, K., Herrenberger, L., Kuespert, S., Fuchshofer, R., Korhonen, H., Wosikowski, K., Jaschinski, F. and Janicot, M.

ARVO, Denver, USA, May 5 2015

2015

Targeting TGF-β2 in chronic liver diseases

Anne Dropmann, Hanna Korhonen, Frank Jaschinski, Michel Janicot, Nadja Meindl-Beinker, Steven Dooley

EASL, Vienna, Austria, April 22-26, 2015

2015

Targeting TGF-β2 in chronic liver diseases

Anne Dropmann, Hanna Korhonen, Frank Jaschinski, Michel Janicot, Nadja Meindl-Beinker, Steven Dooley

GASL, Munich, Germany, January 30-31, 2015

2014

The analysis of a single stranded antisense oligonucleotide in plasma via lysation and hybridization with HPLC-fluorescence

Dick Schoutsen, Erik Baltussen, Rob de Louw, Ingo Röhl, Nadine Dörfler, Katja Wosikowski, Michel Janicot, Theo Noij

EBF – European Bioanalytical Forum, Barcelona, Spain. November 19-21, 2014

2014

Evaluation of Novel Antisense Oligonucleotides Targeting Transforming Growth Factor beta (TGF-β) Isoforms for the Treatment of Ocular Diseases

Hasenbach, K., Wosikowski, K., Jaschinski, F., Korhonen, H., Braun, S. and Janicot, M.

EuroTIDES – Annual Meeting, Berlin, Germany. November 18-19, 2014

2014

Preclinical Profile of ASPH_0047, a Potent and Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-β2)

Wosikowski, K., Jaschinski, F., Korhonen, H., Braun, S., Hasenbach, K., Leo, E. and Janicot, M.

American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago. IL. USA. May 30 – June 3, 2014

2013

Identification and Characterization of Potent and Selective Antisense Oligodeoxynucleotides TargetingTGF-β1 or TGF- β2 mRNA

Jaschinski F., Korhonen H., Braun S., Mitsch A., Rothhammer-Hampl T., Wosikowski K., Janicot M.

EuroTIDES – 14th Annual Meeting

2013 Next-Generation Antisense Oligonucleotides Targeting TGF-β mRNAs Jaschinski F., Korhonen H., Braun S., Mitsch A., Rothhammer-Hampl T., Janicot M. OTS – 9th Annual Meeting of the Oligonucleotide Therapeutics Society

Events & Conferences

Meet us at:

Due to the current COVID-19 situation and its profound impact on scientific, investor and business development conferences worldwide, Isarna will update its corporate calendar as soon as possible. Feel free to reach out, in case you want to learn more about our pipeline projects and potential collaborations.